Horizon Pharma plc Form 4 September 22, 2014

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

**SECURITIES** 

OMB Number:

3235-0287

**OMB APPROVAL** 

Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

if no longer subject to Section 16. Form 4 or

Check this box

Form 5 obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person \* SHERMAN JEFFREY W

2. Issuer Name and Ticker or Trading Symbol Horizon Pharma plc [HZNP]

5. Relationship of Reporting Person(s) to

(Check all applicable)

**EVP** and Chief Medical Officer

Issuer

(Last)

(First)

(Middle)

(Zip)

3. Date of Earliest Transaction

Director X\_ Officer (give title below)

10% Owner Other (specify

C/O HORIZON PHARMA PLC ADELAIDE CHAMBERS, PETER **STREET** 

(State)

(Street) 4. If Amendment, Date Original

Filed(Month/Day/Year)

(Month/Day/Year)

09/19/2014

6. Individual or Joint/Group Filing(Check

Applicable Line)

\_X\_ Form filed by One Reporting Person Form filed by More than One Reporting

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

DUBLIN, L28

(City)

Shares

						• •		•
1.Title of	2. Transaction Date	2A. Deemed	3.	4. Securit	ies Acqui	red 5. Amount of	6. Ownership	7. Nature of
Security	(Month/Day/Year)	Execution Date, if	Transactio	on(A) or Dis	sposed of	Securities	Form: Direct	Indirect
(Instr. 3)		any	Code	(D)		Beneficially	(D) or	Beneficial
		(Month/Day/Year)	(Instr. 8)	(Instr. 3, 4	4 and 5)	Owned	Indirect (I)	Ownership
						Following	(Instr. 4)	(Instr. 4)
					(4)	Reported		
					(A)	Transaction(s)	)	
			Code V	Amount	or (D) Pi	rice (Instr. 3 and 4	)	
0.1			Code v	Amount	(D) Pi	rice		
Ordinary	09/19/2014		$A^{(1)}$	99,298	A (1	99,298	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

# Edgar Filing: Horizon Pharma plc - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Date, if TransactionDerivative Code Securities		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	\$ 13.47	09/19/2014		A(1)	46,335	(2)	06/22/2019	Ordinary Shares	46,335
Stock Option (Right to Buy)	\$ 5.2	09/19/2014		A <u>(1)</u>	47,654	(2)	02/02/2020	Ordinary Shares	47,654
Stock Option (Right to Buy)	\$ 12.94	09/19/2014		A <u>(1)</u>	42,295	(2)	06/15/2020	Ordinary Shares	42,295
Stock Option (Right to Buy)	\$ 4.96	09/19/2014		A <u>(1)</u>	53,621	<u>(4)</u>	12/07/2021	Ordinary Shares	53,621
Restricted Stock Units	<u>(5)</u>	09/19/2014		A <u>(1)</u>	16,416	<u>(6)</u>	<u>(5)</u>	Ordinary Shares	16,416
Stock Option (Right to Buy)	\$ 2.4	09/19/2014		A <u>(1)</u>	51,000	<u>(4)</u>	01/01/2023	Ordinary Shares	51,000
Restricted Stock Units	<u>(5)</u>	09/19/2014		A <u>(1)</u>	33,750	<u>(6)</u>	<u>(5)</u>	Ordinary Shares	33,750
Stock Option (Right to Buy)	\$ 7.61	09/19/2014		A <u>(1)</u>	70,000	<u>(4)</u>	01/01/2024	Ordinary Shares	70,000
Restricted Stock Units	<u>(5)</u>	09/19/2014		A <u>(1)</u>	62,000	<u>(6)</u>	<u>(5)</u>	Ordinary Shares	62,000

### **Reporting Owners**

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

SHERMAN JEFFREY W C/O HORIZON PHARMA PLC ADELAIDE CHAMBERS PETER STREET DUBLIN, L2 8

EVP and Chief Medical Officer

### **Signatures**

/s/ Paul W. Hoelscher, Attorney-in-Fact

09/22/2014

\*\*Signature of Reporting Person

Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
  - Acquisition in connection with the merger (the "Merger") contemplated by the Transaction Agreement and Plan of Merger among Horizon Pharma, Inc., Vidara Therapeutics Holdings LLC, the Issuer (formerly known as Vidara Therapeutics International Ltd.),
- (1) Hamilton Holdings (USA), Inc. and Hamilton Merger Sub, Inc. Pursuant to the Merger, the outstanding securities of Horizon Pharma, Inc. are being canceled and automatically converted into securities of the Issuer. The Reporting Person's disposition of securities of Horizon Pharma, Inc. in the Merger will be reported on a separate Form 4.
- (2) The stock option is fully vested and exercisable. 25% of the shares subject to the option vested on the first anniversary of the grant date, and the remaining shares vested in 36 equal monthly installments thereafter.
- (3) In connection with the Merger, the stock option originally granted by Horizon Pharma, Inc. has been converted into an option to purchase the same number of ordinary shares of the Issuer at the same exercise price and on substantially the same terms.
- (4) The stock option vests in 48 equal monthly installments following the date of grant.
- (5) Each restricted stock unit represented a contingent right to receive one share of Horizon Pharma, Inc. common stock. Each restricted stock unit has been converted into a contingent right to receive one ordinary share of the Issuer.
- (6) The restricted stock units vest in four equal annual installments.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 3